Profile data is unavailable for this security.
About the company
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
- Revenue in INR (TTM)35.60bn
- Net income in INR6.75bn
- Incorporated1924
- Employees3.21k
- LocationGlaxoSmithKline Pharmaceuticals LtdDr Annie Besant Road, WorliMUMBAI 400030IndiaIND
- Phone+91 2 224959595
- Fax+91 2 224981526
- Websitehttps://india-pharma.gsk.com/en-in/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alembic Pharmaceuticals Ltd | 63.57bn | 6.47bn | 204.00bn | 14.86k | 31.56 | 4.17 | 22.06 | 3.21 | 32.88 | 32.88 | 323.14 | 248.68 | 0.929 | 0.9366 | 5.43 | 4,278,678.00 | 9.45 | 10.72 | 13.32 | 14.25 | 73.84 | 65.98 | 10.17 | 12.47 | 0.8057 | 12.62 | 0.1791 | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
Concord Biotech Ltd | 10.86bn | 3.28bn | 208.31bn | 1.38k | 53.76 | 13.10 | 54.58 | 19.19 | 37.04 | 37.04 | 114.79 | 152.02 | 0.655 | 1.11 | 3.55 | 7,884,886.00 | 19.78 | -- | 21.82 | -- | 76.00 | -- | 30.20 | -- | 4.83 | 194.73 | 0.0022 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
Pfizer Ltd | 22.38bn | 6.18bn | 234.75bn | 1.72k | 37.99 | 6.26 | 34.58 | 10.49 | 135.06 | 135.06 | 489.19 | 819.90 | 0.5288 | 1.83 | 11.16 | 13,004,360.00 | 14.60 | 14.22 | 17.05 | 17.71 | 65.00 | 61.37 | 27.61 | 24.05 | 4.30 | 46.21 | 0.0267 | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
Emcure Pharmaceuticals Ltd | 72.56bn | 5.67bn | 242.76bn | 11.15k | 42.27 | 5.89 | 25.28 | 3.35 | 30.37 | 30.37 | 389.63 | 217.79 | 0.978 | 1.80 | 3.96 | 6,510,068.00 | 8.02 | 7.14 | 13.55 | 13.93 | 61.11 | 59.29 | 8.20 | 7.81 | 0.9549 | 5.25 | 0.2165 | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
Natco Pharma Ltd. | 45.61bn | 19.45bn | 246.23bn | 4.02k | 12.66 | 3.44 | 11.54 | 5.40 | 108.58 | 108.58 | 254.65 | 399.19 | 0.6291 | 0.8928 | 3.57 | 11,356,080.00 | 26.82 | 12.33 | 30.85 | 14.25 | 85.47 | 73.05 | 42.63 | 25.16 | 4.19 | 108.70 | 0.0283 | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -4.71 | 14.87 |
Laurus Labs Ltd | 50.53bn | 1.31bn | 263.73bn | 6.01k | 201.06 | 6.38 | 48.37 | 5.22 | 2.43 | 2.43 | 93.70 | 76.70 | 0.602 | 1.18 | 3.06 | 8,412,186.00 | 1.55 | 10.13 | 2.52 | 16.47 | 53.44 | 47.63 | 2.58 | 12.83 | 0.5818 | 1.81 | 0.4023 | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
J B Chemicals and Pharmaceuticals Ltd | 37.11bn | 6.11bn | 264.35bn | 5.31k | 44.27 | 8.23 | 34.40 | 7.12 | 38.45 | 38.45 | 233.33 | 206.82 | 0.9481 | 2.59 | 4.85 | 6,987,882.00 | 15.61 | 15.77 | 18.62 | 18.89 | 66.26 | 61.18 | 16.47 | 16.06 | 2.20 | 27.53 | 0.0303 | 33.08 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
Gland Pharma Ltd | 58.90bn | 6.92bn | 294.41bn | 4.22k | 42.57 | 3.35 | 27.38 | 5.00 | 41.98 | 41.98 | 357.57 | 533.41 | 0.5567 | 1.28 | 4.11 | 13,967,630.00 | 6.54 | 13.23 | 7.65 | 14.56 | 60.30 | 55.58 | 11.74 | 22.92 | 3.14 | 33.11 | 0.0358 | 7.26 | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
Suven Pharmaceuticals Ltd | 9.61bn | 2.43bn | 324.43bn | 1.05k | 133.64 | 16.40 | 106.93 | 33.75 | 9.54 | 9.54 | 37.73 | 77.71 | 0.4156 | 1.52 | 5.99 | 9,136,501.00 | 10.50 | 23.17 | 11.50 | 26.20 | 61.42 | 58.85 | 25.27 | 33.21 | 4.00 | 29.50 | 0.0191 | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
Piramal Pharma Ltd | 87.04bn | 453.30m | 324.55bn | 6.72k | 721.71 | 4.10 | 40.34 | 3.73 | 0.3407 | 0.3407 | 66.36 | 59.91 | 0.5799 | 1.40 | 4.88 | 12,954,040.00 | 0.302 | -- | 0.428 | -- | 63.69 | -- | 0.5208 | -- | 0.5603 | 7.49 | 0.3771 | -- | 15.39 | -- | 109.56 | -- | -- | -- |
Ajanta Pharma Ltd | 44.91bn | 8.75bn | 367.93bn | 7.84k | 42.35 | 10.01 | 36.36 | 8.19 | 69.55 | 69.55 | 356.94 | 294.36 | 0.9738 | 1.33 | 4.16 | 5,725,128.00 | 18.97 | 16.61 | 23.29 | 20.47 | 75.77 | 73.22 | 19.48 | 19.31 | 2.13 | 49.88 | 0.0088 | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
IPCA Laboratories Ltd | 85.33bn | 6.61bn | 399.22bn | 17.34k | 60.37 | 5.96 | 37.42 | 4.68 | 26.07 | 26.07 | 336.37 | 264.10 | 0.7483 | 1.12 | 4.78 | 4,922,642.00 | 5.88 | 10.33 | 9.00 | 13.52 | 67.36 | 59.16 | 7.85 | 12.25 | 1.32 | 25.33 | 0.129 | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
GlaxoSmithKline Pharmaceuticals Limited | 35.60bn | 6.75bn | 401.43bn | 3.21k | 59.84 | 24.00 | 53.99 | 11.27 | 39.60 | 39.60 | 209.31 | 98.74 | 1.01 | 2.59 | 14.85 | 11,088,370.00 | 19.24 | 11.01 | 36.09 | 17.88 | 61.70 | 55.77 | 18.96 | 12.25 | 1.38 | 554.80 | 0.0088 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
Glenmark Pharmaceuticals Ltd | 122.48bn | -10.18bn | 413.80bn | 14.99k | -- | 4.90 | -- | 3.38 | -36.13 | -31.05 | 434.11 | 299.29 | 0.6951 | 1.53 | 4.04 | 8,171,082.00 | -5.64 | 1.02 | -8.51 | 1.43 | 65.64 | 59.47 | -8.11 | 1.43 | 1.00 | 2.56 | 0.1741 | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
Abbott India Ltd | 60.66bn | 12.85bn | 576.17bn | 3.81k | 44.85 | 16.36 | 42.47 | 9.50 | 604.57 | 604.57 | 2,854.72 | 1,657.05 | 1.27 | 5.32 | 15.71 | 15,904,690.00 | 26.82 | 20.92 | 36.97 | 28.59 | 45.09 | 44.20 | 21.18 | 17.26 | 1.71 | 131.36 | 0.0169 | 77.06 | 9.35 | 9.72 | 26.52 | 21.68 | 31.08 | 52.32 |
Holder | Shares | % Held |
---|---|---|
Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2023 | 5.68m | 3.36% |
Kotak Mahindra Asset Management Co. Ltd.as of 31 Oct 2024 | 1.68m | 0.99% |
The Vanguard Group, Inc.as of 06 Nov 2024 | 1.56m | 0.92% |
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Oct 2024 | 1.44m | 0.85% |
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Oct 2024 | 1.40m | 0.82% |
SBI Funds Management Ltd.as of 31 Oct 2024 | 1.27m | 0.75% |
General Insurance Corp. of India (Invt Port)as of 31 Mar 2024 | 1.17m | 0.69% |
quant Money Managers Ltd.as of 31 Oct 2024 | 1.16m | 0.68% |
BlackRock Fund Advisorsas of 07 Nov 2024 | 614.28k | 0.36% |
Dimensional Fund Advisors LPas of 07 Nov 2024 | 466.51k | 0.28% |